Ligand validation:8GK8

BTI: 5-(HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOL-6-YL)PENTANAL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8GK8_BTI_C_1204	65%	41%	0.148	0.949	1.14	1.17	2	3	9	0	100%	1
8GK8_BTI_B_1201	39%	42%	0.227	0.935	1.18	1.09	2	2	2	0	100%	1
8GK8_BTI_A_1201	38%	25%	0.244	0.946	1.29	1.75	2	4	6	0	100%	1
8GK8_BTI_C_1201	33%	36%	0.224	0.901	1.17	1.36	2	3	2	0	100%	1
4HNV_BTI_B_1202	81%	12%	0.123	0.974	1.74	2.3	2	4	9	0	100%	1
3BG5_BTI_B_2000	79%	16%	0.123	0.969	1.63	2.07	2	6	0	0	100%	1
3HO8_BTI_C_2000	76%	13%	0.118	0.955	1.7	2.23	2	3	3	0	100%	1
3HB9_BTI_A_2000	68%	13%	0.148	0.96	1.69	2.22	2	4	1	0	100%	1
3HBL_BTI_B_2000	65%	14%	0.148	0.951	1.62	2.25	2	7	0	0	100%	1
3BG3_BTI_A_2100	74%	14%	0.132	0.961	1.64	2.18	2	3	0	0	100%	1
3N6R_BTI_C_801	72%	14%	0.132	0.955	1.72	2.1	1	6	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.